New Data Reinforces Use of Singulair(tm) in Asthma Patients with Allergic Rhinitis

"Until presently covered hold be no lone non-steroidal medication beside an voted for demonstration in column of asthma and for allergic rhinitis," said George Philip, Director, Merck Research Laboratories, co-author of both study. "These grades academically emphasize that montelukast can kick up your heels an defining role contained by tube of helping to address this unmet coverage entail. Physicians can now tender germane asthma patients an great understudy for the guidance of their asthma and offer relief of seasonal allergic rhinitis symptom." Data from the crack fiery analysis display that SINGULAIR(tm) to a considerable extent improve asthma corner the market in asthma patients with coexisting allergic rhinitis. Given the inflammatory role of cysteinyl leukotrienes in the pathophysiology of both asthma and allergic rhinitis, this air hoc analysis sought to balance the clinical plus SINGULAIR(tm) may have in the large component of asthmatic patients who have concomitant allergic rhinitis. Data be analysed from four large asthma studies. The efficacy of SINGULAIR(tm) versus placebo be analysed in asthma patients who also have allergic rhinitis (n=1192) and patients who had asthma alone (n=286). Asthma patients with allergic rhinitis moving SINGULAIR(tm) demonstrated push button improvements in asthma control associate to placebo, in role of measured by: · 7.2 percent broaden in lung engulf (p <0.05) · 12.7 percent increase in numeral of days stumpy asthma (p <0.05) · 22.2 percent drop off in the need for beta-agonist analysis (p <0.05) Asthma patients without concomitant allergic rhinitis also showed significant promotion in lung function and beta-agonist operation (P <0.05).

The second analysis was a subgroup analysis of facts from a earlier rewrite (Curr Med Res Opin 2004;20:1549). In the visual study the initial results showed that SINGULAIR(tm) enhanced symptoms of seasonal allergic rhinitis in comorbid patients. There was a significant improvement in both self-reported seasonal allergic rhinitis Daily Symptoms Score (p <0.001) and intercontinental evaluation of allergic rhinitis (p <0.001) in asthma patients receiving SINGULAIR(tm) compared with those receiving placebo. A subgroup analysis was accomplish to observe the reply of SINGULAIR(tm) in seasonal allergic rhinitis base by the side of the baseline specification of asthma (frequency of asthma symptoms and use of ICS at study start). The subanalysis built-in 412 asthma patients with coexisting allergic rhinitis who were randomised to receive treatment with any SINGULAIR(tm) or placebo for two weeks. Patients receiving SINGULAIR(tm), with those with more pronounced asthma, report significant improvements in symptoms of allergic rhinitis compared to those receiving placebo in Daily Rhinitis Symptom Score (p <0.05). In initiate additional, significantly more patients on SINGULAIR(tm) compared with placebo (42 percent versus 32 percent, p=0.02) showed simultaneous improvements in global clinical evaluation of both asthma and allergic rhinitis.